Continue Going Beyond Green, Yellow, Red on the GeneSight® Report

Our expert panel of GeneSight® users went in-depth, going beyond the green, yellow, red bins to optimize the appropriate utility of your GeneSight Psychotropic Report.

The GeneSight Psychotropic Report provides information about which medications may require dose adjustments, be less likely to work or have an increased risk of side effects based on your genetic information.

In this webinar, we discussed how to interpret the GeneSight report, expanding upon the effect of smoking on the metabolism of certain psychotropic medications, and reviewing new data from a real-world study of healthcare utilization for over 20,000 GeneSight tested patients with MDD.

During this webinar, our panel of providers drew from their clinical expertise to answer questions live and discuss topics such as:
Have patient outcomes been assessed when utilizing the GeneSight Psychotropic report?
What does it mean if a medication is in the green bin and why might I see some medications there more frequently than others?
How might smoking affect my patients' GeneSight results?
Will my patients' GeneSight Psychotropic report change over time?

Our panelists were:
Ann Groover, MD
Owner & Medical Director, The Groover Clinic, LLC

Bernie Ranchero, MD, MS, MBA
Medical Director, Leadwell Division, Hospital Sisters Healthy System

Carson Felkel, MD, FAPA
System Medical Director, Bon Secours Mercy Health

Moderated By:
Rachael Earls, PhD
Medical Science Liaison Manager, Myriad Genetics